Literature DB >> 26332942

High-density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin-1.

Man K S Lee1,2, Xiao-Lei Moore1, Yi Fu1, Annas Al-Sharea1,2, Dragana Dragoljevic1,2, Manuel A Fernandez-Rojo3, Robert Parton4, Dmitri Sviridov1, Andrew J Murphy1,5, Jaye P F Chin-Dusting1,2.   

Abstract

BACKGROUND AND
PURPOSE: Monocyte-derived macrophages are critical in the development of atherosclerosis and can adopt a wide range of functional phenotypes depending on their surrounding milieu. High-density lipoproteins (HDLs) have many cardio-protective properties including potent anti-inflammatory effects. We investigated the effects of HDL on human macrophage phenotype and the mechanisms by which these occur. EXPERIMENTAL APPROACH: Human blood monocytes were differentiated into macrophages in the presence or absence of HDL and were then induced to either an inflammatory macrophage (M1) or anti-inflammatory macrophage (M2) phenotype using LPS and IFN-γ or IL-4, respectively. KEY
RESULTS: HDL inhibited the induction of macrophages to an M1-phenotype, as evidenced by a decrease in the expression of M1-specific cell surface markers CD192 and CD64, as well as M1-associated inflammatory genes TNF-α, IL-6 and MCP-1 (CCL2). HDL also inhibited M1 function by reducing the production of ROS. In contrast, HDL had no effect on macrophage induction to the M2-phenotype. Similarly, methyl-β-cyclodextrin, a non-specific cholesterol acceptor also suppressed the induction of M1 suggesting that cholesterol efflux is important in this process. Furthermore, HDL decreased membrane caveolin-1 in M1 macrophages. We confirmed that caveolin-1 is required for HDL to inhibit M1 induction as bone marrow-derived macrophages from caveolin-1 knockout mice continued to polarize into M1-phenotype despite the presence of HDL. Moreover, HDL decreased ERK1/2 and STAT3 phosphorylation in M1 macrophages. CONCLUSIONS AND IMPLICATIONS: We concluded that HDL reduces the induction of macrophages to the inflammatory M1-phenotype via redistribution of caveolin-1, preventing the activation of ERK1/2 and STAT3.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26332942      PMCID: PMC4742290          DOI: 10.1111/bph.13319

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Antiinflammatory actions of HDL: a new insight.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11       Impact factor: 8.311

4.  Lipocalin 2 is a regulator of macrophage polarization and NF-κB/STAT3 pathway activation.

Authors:  Hong Guo; Daozhong Jin; Xiaoli Chen
Journal:  Mol Endocrinol       Date:  2014-08-15

5.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 6.  High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.

Authors:  Jonathan E Feig; Bernd Hewing; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

7.  The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis.

Authors:  Ioana Madalina Fenyo; Anca Violeta Gafencu
Journal:  Immunobiology       Date:  2013-06-19       Impact factor: 3.144

8.  Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts.

Authors:  Alex W Cohen; David S Park; Scott E Woodman; Terrence M Williams; Madhulika Chandra; Jamshid Shirani; Andrea Pereira de Souza; Richard N Kitsis; Robert G Russell; Louis M Weiss; Baiyu Tang; Linda A Jelicks; Stephen M Factor; Vitaliy Shtutin; Herbert B Tanowitz; Michael P Lisanti
Journal:  Am J Physiol Cell Physiol       Date:  2002-10-09       Impact factor: 4.249

9.  Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.

Authors:  Sathish Babu Vasamsetti; Santosh Karnewar; Anantha Koteswararao Kanugula; Avinash Raj Thatipalli; Jerald Mahesh Kumar; Srigiridhar Kotamraju
Journal:  Diabetes       Date:  2014-12-31       Impact factor: 9.461

10.  High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

Authors:  Dominic De Nardo; Larisa I Labzin; Hajime Kono; Reiko Seki; Susanne V Schmidt; Marc Beyer; Dakang Xu; Sebastian Zimmer; Catharina Lahrmann; Frank A Schildberg; Johanna Vogelhuber; Michael Kraut; Thomas Ulas; Anja Kerksiek; Wolfgang Krebs; Niklas Bode; Alena Grebe; Michael L Fitzgerald; Nicholas J Hernandez; Bryan R G Williams; Percy Knolle; Manfred Kneilling; Martin Röcken; Dieter Lütjohann; Samuel D Wright; Joachim L Schultze; Eicke Latz
Journal:  Nat Immunol       Date:  2013-12-08       Impact factor: 25.606

View more
  21 in total

1.  Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

Authors:  Bradley K Wacker; Nagadhara Dronadula; Lianxiang Bi; Alexis Stamatikos; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-09       Impact factor: 8.311

2.  HDL and Diabetes.

Authors:  Blake J Cochran; Bikash Manandhar; Kerry-Anne Rye
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  5-Fluorouracil Treatment of CT26 Colon Cancer Is Compromised by Combined Therapy with IMMODIN.

Authors:  Vlasta Demeckova; Dagmar Mudronova; Sona Gancarcikova; Peter Kubatka; Karol Kajo; Monika Kassayova; Bianka Bojkova; Marian Adamkov; Peter Solár
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

4.  High-density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin-1.

Authors:  Man K S Lee; Xiao-Lei Moore; Yi Fu; Annas Al-Sharea; Dragana Dragoljevic; Manuel A Fernandez-Rojo; Robert Parton; Dmitri Sviridov; Andrew J Murphy; Jaye P F Chin-Dusting
Journal:  Br J Pharmacol       Date:  2015-10-30       Impact factor: 8.739

5.  Inflammation: maladies, models, mechanisms and molecules.

Authors:  A G Stewart; P M Beart
Journal:  Br J Pharmacol       Date:  2016-02       Impact factor: 8.739

Review 6.  The cholesterol pathway: impact on immunity and cancer.

Authors:  Ryan J King; Pankaj K Singh; Kamiya Mehla
Journal:  Trends Immunol       Date:  2022-01       Impact factor: 16.687

7.  Loganin inhibits macrophage M1 polarization and modulates sirt1/NF-κB signaling pathway to attenuate ulcerative colitis.

Authors:  Shi Liu; Hui Shen; Jiyan Li; Ying Gong; Haidong Bao; Jingyuan Zhang; Lanqing Hu; Zhengpeng Wang; Jian Gong
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 8.  Leptin in Atherosclerosis: Focus on Macrophages, Endothelial and Smooth Muscle Cells.

Authors:  Priya Raman; Saugat Khanal
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 9.  Lipid regulation of NLRP3 inflammasome activity through organelle stress.

Authors:  Jonathan J Liang; Iain D C Fraser; Clare E Bryant
Journal:  Trends Immunol       Date:  2021-07-30       Impact factor: 19.709

Review 10.  Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis.

Authors:  Yuri V Bobryshev; Ekaterina A Ivanova; Dimitry A Chistiakov; Nikita G Nikiforov; Alexander N Orekhov
Journal:  Biomed Res Int       Date:  2016-07-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.